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Abstract
Buruli ulcer (BU), caused by infection withMycobacterium ulcerans, is a chronic necrotizing
human skin disease associated with the production of the cytotoxic macrolide exotoxin
mycolactone. Despite extensive research, the type of immune responses elicited against
this pathogen and the effector functions conferring protection against BU are not yet fully
understood. While histopathological analyses of advanced BU lesions have demonstrated a
mainly extracellular localization of the toxin producing acid fast bacilli, there is growing evi-
dence for an early intra-macrophage growth phase ofM. ulcerans. This has led us to investi-
gate whether interferon-γmight play an important role in containingM. ulcerans infections. In
an experimental Buruli ulcer mouse model we found that interferon-γ is indeed a critical regu-
lator of early host immune defense againstM. ulcerans infections. Interferon-γ knockout
mice displayed a faster progression of the infection compared to wild-type mice. This accel-
erated progression was reflected in faster and more extensive tissue necrosis and oedema
formation, as well as in a significantly higher bacterial burden after five weeks of infection,
indicating that mice lacking interferon-γ have a reduced capacity to kill intracellular bacilli dur-
ing the early intra-macrophage growth phase ofM. ulcerans. This data demonstrates a prom-
inent role of interferon-γ in early defense againstM. ulcerans infection and supports the view
that concepts for vaccine development against tuberculosis may also be valid for BU.
Author Summary
Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU), a slow progressing
ulcerative skin disease. The mode of transmission ofM. ulcerans remains unknown and
only little is known about the early stages of the disease and the nature of protective
immune responses against this pathogen. Given the increasing evidence for an early intra-
cellular growth phase ofM. ulcerans, we aimed at evaluating the impact of cell-mediated
immunity for immunological defense againstM. ulcerans infections. By comparing wild-
type and interferon-γ-deficient mice in a BU mouse model, we could demonstrate that
interferon-γ is a critical regulator of early host immune defense againstM. ulcerans infec-
tions, indicative for an important role of early intracellular multiplication of the pathogen.
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In mice lacking interferon-γ the bacterial burden increased faster, resulting in accelerated
pathogenesis. The observed differences between the two mouse strains were most likely
due to differences in the capacity of macrophages to kill intracellular bacilli during the
early stages of infection.
Introduction
Buruli ulcer (BU), caused by infection withMycobacterium ulcerans (M. ulcerans), is a progres-
sive disease of the skin and subcutaneous tissue. The disease is primarily affecting West African
rural communities, but has also been reported from America, Australia and Asia. The patho-
genesis of BU is mainly attributed to mycolactone, a macrolide exotoxin produced byM. ulcer-
ans [1]. Mycolactone is essential for bacterial virulence and is highly cytotoxic for a wide range
of mammalian cell types in vitro and in vivo, including fibroblasts, keratinocytes and adipo-
cytes [1–4]. Injection of the toxin induces the formation of necrotic non-inflammatory lesions
similar to BU lesions. In addition to the induction of apoptosis, mycolactone possesses immu-
nosuppressive characteristics and has been demonstrated to downregulate local and systemic
immune responses [5,6], by interfering with the activation of immune cells such as T-cells, den-
dritic cells, monocytes and macrophages [7–10]. Furthermore, exposure to mycolactone results
in complete inhibition of tumor necrosis factor alpha (TNFα) production by monocytes and
macrophages, affects T-cell homing and interferes with the expression of T-cell receptors as
well as co-stimulatory molecules including CD40 and CD86 [6–12].
Despite these immunosuppressive features of mycolactone, sera of individuals living in BU
endemic regions frequently containM. ulcerans-specific antibodies, demonstrating that many
individuals develop immune responses associated with exposure toM. ulcerans without devel-
oping clinical disease [13,14]. Moreover, high mRNA levels for the cytokines interferon-γ
(IFNγ), interleukin-1β and TNF-α were found in human BU lesions, indicating that the innate
immune system is activated at the site of infection [15]. Reports on spontaneous healing of BU
[16,17], and a partial protective effect of Bacille Calmette-Guérin (BCG) vaccination in humans
and experimentally infected mice [18–22] are all factors indicating that clearance of theM.
ulcerans infection by the immune system is possible, in particular before large clusters of myco-
lactone producing extracellular bacteria have formed. These clusters are located in necrotic sub-
cutaneous tissue of advanced BU lesions and are no longer reached by infiltrating leukocytes.
Antibodies against surface antigens ofM. ulcerans do not seem to have a protective effect
[23], indicating that cellular, and in particular type 1 helper (TH1) cell responses [1,24] are
more important in immune defense against BU than humoral responses.
IFNγ is critical for host defense against intracellular pathogens. InMycobacterium tubercu-
losis (M. tuberculosis) infections, IFNγ produced by TH1 cells, but also CD8 cytotoxic T (Tc)
cells and NK cells, renders the macrophage competent to kill intracellular bacteria by overcom-
ing the pathogen-induced block in phagosome-lysosome fusion and by producing microbicidal
effectors such as nitric oxide (NO), resulting in host cell apoptosis and clearance of the bacteria
[25–28]. DuringM. ulcerans infection, an early intra-macrophage growth phase seems to play
an important role before the formation of extracellular clusters of mycolactone producing bac-
teria can be observed [6,29–31]. Protection mediated by IFNγ stimulated macrophages seems
to be impaired by the suppression of IFNγ production after local build-up of mycolactone [32].
Here we have re-evaluated the role of IFNγ for host immune defense againstM. ulcerans by
comparing progression of the infection in IFNγ knockout and wild-type mice experimentally
challenged with a fully virulentM. ulcerans isolate.
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Methods
Ethical statement
This study was carried out in strict accordance with the Rules and Regulations for the Protec-
tion of Animal Rights (Tierschutzgesetz SR455) of the Swiss Federal Food Safety and Veteri-
nary Office. The protocol was granted ethical approval by the Veterinary Office of the county
of Vaud, Switzerland (Authorization Number: 2657).
Mouse procedures
Mice were kept in specific pathogen-free facilities at the Ecole Polytechnique Fédérale de Lau-
sanne (EPFL), Switzerland. All experiments were performed under BSL-3 conditions either in
8 week old female C57Bl/6 wild-type mice or mice homozygous for the Ifngtm1Ts targeted
mutation (IFNγ-/-, B6.129S7-Ifngtm1Ts/J, Jackson Laboratory). In total, 20 wild-type and 20
IFNγ-/- mice were infected and 5 animals per group were euthanized at week 1, 3, 5 and 8 and
used for qPCR analysis (3 mice) or histopathology (2 mice). The experiment was performed in
two independent biological replicates. Animals were infected with theM. ulcerans strain S1013
isolated in 2010 from the ulcerative lesion of a BU patient from Cameroon [33] which is regu-
larly tested for the production of mycolactone by ASL extraction and subsequent cytotoxicity
tests on L929 fibroblasts as well as for the presence of the virulence plasmid pMUM001 by
PCR. The bacteria were cultivated from a low passage cell bank for six weeks in Bac/T medium
(Biomerieux, 251011), pelleted by centrifugation and diluted in sterile PBS to a stock concen-
tration of 125 mg/ml wet weight. Mice were infected subcutaneously into the hind left foot pad
with 30 μl (about 1 x 104 bacilli as determined by qPCR corresponding to 5 x 103 CFUs when
plated on 7H9 ager plates) of an appropriate dilution of the stock suspension in sterile PBS.
Progression of the infection was followed by weekly measurements of the foot pad thickness
using a caliper. At weeks 1, 3, 5 and 8, groups of mice were euthanized and pictures of the feet
were taken using a compact camera (WG-20, RICOH). The foot pads were aseptically removed
for determination of the bacterial load by quantitative real-time PCR (qPCR) or for histopatho-
logical analysis.
Determination of bacterial load by qPCR
Feet designated for the quantification ofM. ulcerans were cut into 4 pieces using a scalpel and
transferred to hard tissue grinding tubes (MK28-R, Precellys, KT03961-1-008.2). Next, 750 μl
sterile PBS was added and feet were homogenized using a Precellys 24-Dual tissue homoge-
nizer (3 x 20 s at 5000 rpm with 30 s break). The lysates were transferred into new tubes and
the remaining tissues were homogenized for a second time after adding 750 μl of sterile PBS.
The two lysates were pooled and used for DNA isolation. The DNA was extracted from 100 μl
of a 1/20 dilution of the foot pad lysates as described by Lavender and Fyfe [34] and the isolated
DNA was analyzed for insertion sequence (IS) 2404 by qPCR as previously described [34]. The
number of genomes per foot pad was calculated according to the standard curve established by
Fyfe et al. [35].
Histopathology
Mouse feet used for histopathological analysis were fixed in 10% neutral-buffered formalin
solution (4% formaldehyde, Sigma, HT501128-4L) for 24 hours at room temperature, decalci-
fied in 0.6 M EDTA and 0.25 M citric acid for 14 days at 37°C and transferred to 70% EtOH for
storage. After dehydration and embedding in paraffin, 5 μm thin sections were cut. Sections
were then deparaffinised, rehydrated, and stained with Haematoxylin/Eosin (HE, Sigma,
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51275-500ML, J.T. Baker, 3874) or Ziehl-Neelsen/Methylene blue (ZN, Sigma, 21820-1L and
03978-250ML) to stain for mycobacteria according to WHO standard protocols [36]. Finally,
the sections were mounted with Eukitt mounting medium (Fluka, 03989) and pictures were
taken with an Aperio scanner or with a Leica DM2500B microscope.
Western blot analysis
Ten μg ofM. ulcerans whole cell lysate was resolved on a 1-well 4–12% gradient gel (NuPAGE
Novex 4–12% Bis-Tris Gel, Invitrogen, NP0330BOX) using MES running buffer and trans-
ferred to nitrocellulose membranes with the iBlot dry-blotting system (Novex, Life Technolo-
gies) according to the manufacturer’s recommendations. The membrane was blocked in 5%
skim milk / PBS overnight at 4°C, cut into thin strips and incubated with the indicated sera
diluted 1:400 in 1% skim milk / PBS-Tween-20 for 1.5 hours. After washing in 1% skim milk /
PBS-Tween-20, the membrane was incubated for 1 hour with HRP-conjugated goat anti-
mouse IgG γ-chain secondary antibody (Southern Biotech, 1030–05) diluted 1:4000 in 1%
skim milk / PBS-Tween-20. Blots were developed using the ECLWestern Blotting Substrate
(Pierce, 32106).
Statistics
A non-parametric Mann-Whitney test (Prism GraphPad) was used for statistical analysis of
foot pad thickness measurements. Because of the small sample size for each group at a certain
time point, the measurements of the bacterial loads were analyzed using non-parametric
regression models according to the Brunner-Langer method [37]. The factor of interest,
increase in bacterial burden between week 3 and 5 in the case of (1) and bacterial burden at
week 5 in the case of (2) was included in a model to determine its effect on the examined out-
come. In (1), because all 4 time points are compared in a second model, results from the
regressions were adjusted for multiple comparisons using Dunnett-Hsu’s correction. The
global effect of group, time point and of the interaction of group by time point were first tested
[38].
Results
M. ulcerans infections progress faster in mice lacking IFNγ
In order to evaluate the role of IFNγ in host immune defense againstM. ulcerans infections, we
infected 8 week old female C57Bl/6 wild-type (WT) mice and mice homozygous for the
Ifngtm1Ts targeted mutation (IFNγ-/-) into the left hind foot pad with 1 x 104 M. ulcerans bacilli
as determined by qPCR. Progression of the disease was followed by weekly measurements of
the foot pad thickness with a caliper. While all of the ten IFNγ-/- mice displayed strong swelling
of the infected foot pads after 5 weeks of infection, no swelling was observed for the ten WT
animals (Fig 1A). After 6 weeks of infection, one of the remaining five WT animals also started
to show swelling of the infected feet. However, there was still a significant difference in foot
pad thickness between the two different groups, which only resolved by week 8 (Fig 1A).
Complementary to the determination of the foot pad thickness, we documented the disease
progression with pictures of the infected feet at 1, 3, 5 and 8 weeks after infection (Fig 1B). At
week 5 infected foot pads of all ten WTmice did not show any macroscopic difference to the
non-infected right control foot pads (Fig 1B). In contrast, all infected feet of the ten IFNγ-/-
mice were swollen and showed signs of inflammation (Fig 1B). Although the difference in the
foot pad thickness resolved after 8 weeks of infection, the infected feet of the IFNγ-/- animals
were more inflamed and clearly more ravaged at this time point (Fig 1B).
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Fig 1. Faster progression ofM. ulcerans infection in IFNγ-deficient mice.WT and IFNγ-/- mice were
infected into the left hind foot pad withM. ulcerans and the progression of the disease was followed by weekly
measurements of the foot pad thickness (A) and documented with pictures of the infected feet (B). (A) IFNγ-/-
mice exhibited an accelerated progression ofM. ulcerans infection. At weeks 5 and 6, the foot pad thickness
was significantly higher in IFNγ-/- mice than in WT animals. Mean values of the foot pad thickness (mm) are
Role of Interferon-γ inM. ulcerans Infections
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IFNγ-deficient mice display more extensive tissue necrosis and oedema
formation than WTmice
Histopathological analysis of two representative foot pads was performed to evaluate whether
the increased foot pad thickness in IFNγ-/- mice at week 5 was caused by cellular infiltration or
mainly by oedema formation. While no changes in tissue integrity were observed after 1 week
of infection in both groups (Fig 2A1–2A3 and 2B1–2B3), the two IFNγ-/- mice displayed mas-
sive oedema formation and tissue necrosis after 5 weeks of infection (Fig 2B5, 2B4 and 2B6,
respectively). Both are typical hallmarks of BU pathogenesis [39,40]. In contrast, the foot pads
of the two WT animals were devoid of oedema formation or tissue necrosis at this time point
(Fig 2A4–2A6). Eight weeks after infection the foot pads of the IFNγ-/- mice were still more
oedematous and necrotic than those of the WT animals and the infection even affected the
adjacent joints and legs (Fig 2A7–2A9 and 2B7–2B9).
Enhanced bacterial multiplication in IFNγ-deficient mice
Next, we assessed whether the more severe course ofM. ulcerans infection in the IFNγ-/- mice
was associated with a higher bacterial burden in these animals. The bacterial load in footpads
of three WT and three mutant mice was determined 1, 3, 5 and 8 weeks after infection by
qPCR [23,34,35]. Strikingly, IFNγ-/- mice showed a significantly higher increase in the bacterial
load between week 3 and 5 (Fig 3A). Furthermore, we found that the bacterial load in the mice
lacking IFNγ was significantly (3.5 fold) higher after 5 weeks of infection than in WTmice (Fig
3A), correlating with the strong foot pad swelling observed at this time point in only the
mutant mice (Fig 1A and 1B). As for the foot pad thickness, the differences in the bacterial
load had resolved 8 weeks after infection (Fig 3A).
To complement the qPCR results we stained tissue sections of whole foot pads with ZN to
detect AFB. After 3 weeks of infection, only few AFB were found which were predominantly
intracellular (Fig 3B1 and 3B2). As for the qPCR analysis (Fig 3A), no difference in the total
number of AFB was observed between the two groups at this time point. However, a trend to
less extracellular bacterial debris and more intact extracellular bacilli was observed for IFNγ-/-
foot pads at this time (S1 Fig).
In contrast, more AFB were detected in both IFNγ-/- mice 5 weeks after infection (Fig 3C3
and 3C4), as compared to the twoWT controls (Fig 3C1 and 3C2), which again corresponded
with the results of the qPCR analysis (Fig 3A). At this time point, AFB were present as a mix of
intra- and extracellular bacteria (Fig 3C). Interestingly, while the bacterial load was different
for the two groups at this time point, no marked differences in the total cell infiltration was
observed (Fig 3C). In line with the findings from the qPCR analysis (Fig 3A), the differences in
the bacterial load had resolved 8 weeks after infection (S2 Fig).
Lack of antibody responses againstM. ulcerans after 5 and 8 weeks of
infection
To evaluate whether the stronger increase in the bacterial load between weeks 3 and 5 in the
IFNγ-/- mice (Fig 3A) was caused by a diminished innate immune response as a result of lack
shown, the error bars represent the S.D. P values were calculated using non-parametric Mann-Whitney test.
****, P 0.0001; *, P 0.05; n.s., not significant. (B) Pictures of representative feet taken 1, 3, 5 and 8
weeks after infection. At week 5, all mice deficient for IFNγ-/- had swollen feet. No swelling was observed in
WTmice at this time point. Eight weeks after infection, foot pad swelling was observed for both WT and
IFNγ-/- mice but the macroscopic disease symptoms were more severe in mice lacking IFNγ. Scale bars
represent 5 mm.
doi:10.1371/journal.pntd.0004450.g001
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of activating IFNγ or rather by reduced antibody-mediated immune responses againstM.
ulcerans, we tested the reactivity of sera of infected mice withM. ulcerans whole cell lysates by
Western Blot analysis. A complete absence of specific antibodies was observed both for the five
WT and five IFNγ-/- mice after 5 and 8 weeks of infection (Fig 4). Together with the observed
presence of less extracellular debris in IFNγ-/- mice during the early phase of the infection (S1
Fig), this indicates that CMI is critical for host immunity againstM. ulcerans infections.
Discussion
Evidence for an early intra-macrophage growth phase ofM. ulcerans has led to the suggestion
that the immune effector mechanisms protecting againstM. ulcerans infection are similar to
those active againstM. tuberculosis [41–43]. However, in contrast to this closely related patho-
gen,M. ulcerans has the capacity to produce the cytotoxic macrolide mycolactone, which
Fig 2. Extensive tissue necrosis and oedema formation in mice lacking IFNγ. HE stained histologic sections of foot pads from representative WT (A)
and IFNγ-/- (B) mice 1, 5 and 8 weeks after infection withM. ulcerans. Scale bars represent 5 mm (A1, A4, A7, B1, B4 and B7, left), 1 mm (A1, A4, A7, B1, B4
and B7, box), 150 μm (A2, A5, A8, B2, B5 and B8) and 80 μm (A3, A6, A9, B3, B6 and B9).
doi:10.1371/journal.pntd.0004450.g002
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Fig 3. IFNγ-deficient mice have a significantly higher bacterial burden 5 weeks after infection.WT and IFNγ-/- mice were infected withM. ulcerans and
the bacterial load was determined by IS2404-specific qPCR (A). The distribution of AFB in the footpads was assessed by histopathological analysis at week
3 (B) and week 5 (C). (A) IFNγ-/- mice showed a significantly stronger increase in the bacterial burden between week 3 and 5 (1) and had a significantly higher
bacterial burden as compared to WT animals 5 weeks after infection withM. ulcerans (2). Values are displayed as mean, the error bars represent the S.D.
(n = 3 per genotype). P values were calculated using non-parametric regression models according to the Brunner-Langer method. *, P 0.05. (B and C)
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eventually kills the host cells and causes the characteristic necrotizing pathology of BU [1,40].
In the case ofM. tuberculosis infection, the host immune response involves cell-mediated
immunity (CMI) accompanied by a delayed type hypersensitivity (DTH) reaction [44]. Simi-
larly, several reports showed that CMI and DTH responses are frequently induced in BU
patients [43,45–50].
If CMI is required for immunological defense againstM. ulcerans infections, IFNγ which is
produced primarily by TH1, but also by TC and NK cells, is likely to play a critical role in this
process by activating macrophages to kill intracellular bacteria at an early stage of infection. To
test this hypothesis, we have used an experimental BU mouse model and compared the disease
progression in WT and IFNγ-/- mice during active infection with a highly virulentM. ulcerans
strain recently isolated from the lesion of a BU patient [33]. Our study conclusively demon-
strates a key role of IFNγ for early immune defense againstM. ulcerans infection in vivo, as
mice lacking this cytokine suffered from an accelerated and more severe pathology associated
with a significantly higher bacterial burden after 5 weeks of infection. These results indicate
that CMI and IFNγ-dependent activation of the bactericidal activity of macrophages helps to
contain the infection during its largely intracellular early stages. Further support for this
hypothesis came from our histopathological analysis, where a trend to lower levels of extracel-
lular acid-fast debris was found in the IFNγ-/- mice at the early intracellular stages of the
infection.
Moreover, these findings are in line with the observation of Torrado et al. who have reported
that IFNγ-dependent phagosome maturation and NO production are required to control the
intracellular proliferation ofM. ulcerans in vitro [32]. In the same report, it is described, that
IFNγ-deficient mice show increased susceptibility only for mycolactone-negative or
5 μm tissue sections of foot pads from representative WT (left) and IFNγ-/- (right) mice stained with ZN for visualization of AFB after 3 (B) or 5 (C) weeks of
infection. AFB were predominantly intracellular at week 3 (B1 and B2, black arrows) whereas a mix of intra- and extracellular bacilli was found after 5 weeks
of infection (C). At week 5, more AFB were present in IFNγ-/- foot pads (C2 and C4), no difference in the total immune cell infiltration between the two groups
was observed (C1 and C3). Scale bars represent 8 μm (B1 and B2), 160 μm (C1 and C3) and 40 μm (C2 and C4).
doi:10.1371/journal.pntd.0004450.g003
Fig 4. Absence of specific antibody responses againstM. ulcerans in infectedWT and IFNγ-/- mice.
Sera of WT and IFNγ-/- mice were analyzed 5 and 8 weeks after infection for the presence of specific IgG
antibody responses againstM. ulcerans byWestern blotting onM. ulceranswhole cell lysate. A monoclonal
antibody specific for theM. ulcerans antigen MUL3720 served as positive control.
doi:10.1371/journal.pntd.0004450.g004
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intermediate virulent, but not for highly virulentM. ulcerans strains [32]. However, these at
first view contradictory results can be explained by the fact that the mice infected by Torrado
et al. with a highly virulentM. ulcerans strain were only monitored over a period of 20 days
post infection, a time frame that is too narrow to detect the differences between WT and
IFNγ-/- mice, as we did not observe them before 5 weeks of infection. In addition, differentM.
ulcerans strains differing in the geographic origin, the mycolactone variants produced and the
pattern of genomic changes associated with evolutionary genome reduction [51] were used by
the two groups.
In conclusion, our results indicate that the outcome of an infection withM. ulceransmay
depend strongly on cellular immune defense mechanisms. IFNγ is likely to play an important
role both as an element of innate immunity in the very early phase of host-pathogen interaction
after inoculation and also in the subsequent development of protective adaptive cellular immune
responses. Innate and adaptive immune defense mechanisms seem to be strong enough in the
majority of exposed individuals living in BU endemic areas to protect them from developing
clinical disease [13,14]. However, when the immune response of an individual is too weak to kill
the intracellular bacteria, BU disease may develop. In line with this, HIV positive individuals are
at higher risk for BU and AIDS-associated immunosuppression has a negative influence on the
severity of BU [52–54]. In the case of an insufficient immune response, intracellular multiplica-
tion of the bacteria may take place and small accumulations of bacteria found as globus-like
structures [30,55] may represent the origin for the formation of large clusters of mycolactone
producingM. ulcerans bacteria. As a result of mycolactone-induced host cell apoptosis, necrotic
areas are forming around the bacteria. Furthermore, in the advanced BU lesions viable leukocyte
infiltrates are no longer found close to the infection foci in the necrotic subcutaneous tissue,
indicating that the accumulation of mycolactone is preventing macrophages and other defense
cells from reaching the now extracellular pathogens before they are killed. As a result, a chronic
M. ulcerans infection may develop, leading to the formation of large BU lesions, often resulting
in severe morbidity and disability and requiring long and costly hospitalization [40].
Supporting Information
S1 Fig. IFNγ-deficient mice show lower amounts of bacterial debris and higher numbers of
intact extracellular bacteria 3 weeks after infection.Histologic analysis of foot pad sections
from representative WT (left) and IFNγ-/- (right) infected for 3 weeks of infection withM.
ulcerans. Arrows indicate bacterial debris (left) or intact AFB (right). Scale bars, 8 μm.
(TIF)
S2 Fig. No differences in the amount of AFB after 8 weeks of infection.Histologic sections
of foot pads from representative WT (left) and IFNγ-/- (right) mice infected for 8 weeks with
M. ulcerans stained with ZN for AFB visualization. Scale bars, 30 μm.
(TIF)
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